분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-12-20 13:04:01 , Hit : 537
 Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness

https://www.marketwatch.com/story/spark-therapeutics-shares-rise-on-fda-approval-of-new-gene-therapy-for-blindness-2017-12-19-1191742

Published: Dec 19, 2017 11:07 a.m. ET  

By Emma Court
Reporter

Spark Therapeutics Inc. ONCE, -0.22% shares rose 3% in heavy morning trade Tuesday after the company's gene therapy Luxturna was approved by the Food and Drug Administration for a rare type of inherited vision loss. Just one administration of the therapy could treat the disease, making it a major scientific breakthrough. The approval had been widely expected after an FDA committee recommended it in October, and was heralded by FDA Commissioner Scott Gottlieb as "another first in the field of gene therapy." The next, major question for the therapy is price, with some analysts projecting the cost could come close to $1 million. Gene therapies, the first of which was approved this past summer, are expected to challenge existing U.S. payment structures with their price tags, which are extremely high and cover a one-time treatment. Luxturna was approved for individuals with confirmed biallelic RPE65 mutation-associated retinal dystrophy, which is part of a group of eye disorders caused by gene mutations, can cause complete blindness in some cases and affects about 1,000 to 2,000 people in the U.S. Spark shares have plummeted 41.5% over the last three months, compared with a 7.2% rise in the S&P 500 SPX, -0.32% and a 10.8% rise in the Dow Jones Industrial Average DJIA, -0.15%







27   Nonviral CRISPR Delivery a Success  이성욱 2017/10/03 692
26   [미국] 2017년, 유전자가위 기술을 통한 네 가지 사건들  이성욱 2018/01/10 691
25   Scientists Doubt Results of CRISPR’d Embryos  이성욱 2017/09/02 682
24   Alcohol Boosts Cancer Risk by Damaging Stem Cell DNA  이성욱 2018/01/05 676
23   Shields Up for New Cancer Gene-Therapy Virus  이성욱 2018/02/01 675
22   작년 바이오산업 규모 8조8775억원, 투자 13.9% 늘어  이성욱 2017/12/13 670
21   FDA Approves First Gene Therapy for Inherited Disease  이성욱 2017/12/22 668
20   릴리 '시람자' 간암 말기 임상시험 성공  이성욱 2018/04/07 657
19   Giants of Circadian Biology Win Nobel Prize  이성욱 2017/10/03 655
18   Technique Adapted from CRISPR-Cas9 Corrects Mutation in Human Embryos  이성욱 2017/09/29 654
17   CRISPR/Cas9 Edits Epigenome with Therapeutic Efficiency  이성욱 2017/12/09 638
16   CRISPR-Cas9 Improved 10,000-Fold by Synthetic Nucleotides  이성욱 2018/04/17 627
15   Powerful enzyme could make CRISPR gene-editing more versatile  이성욱 2018/03/01 616
14   CRISPR’s MAGESTIC Evolution Makes Gene Editing More Precise  이성욱 2018/05/08 595
13   Cause of CRISPR Failure Identified and Reversed  이성욱 2018/07/12 552
  Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness  이성욱 2017/12/20 537
11   CRISPR-Cas12a More Precise Than CRISPR-Cas9  이성욱 2018/08/07 534
10   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 526
9   [바이오토픽] 유전자를 침묵시키는 신약, 20년의 기다림 끝에 승인  이성욱 2018/08/13 525
8   Doubts arise again about CRISR'd human embryos  이성욱 2018/08/09 519

[이전 10개] [1]..[61][62] 63 [64]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN